Barrett's Esophagus & Gastroesophageal Reflux Disease
The Valley Hospital Center for Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Barrett's esophagus (BE) is a known premalignant condition of the esophagus, predisposing to the development of esophageal adenocarcinoma. BE represents a change in the lining (mucosa) of the esophagus which is known to be produced as a result of chronic gastroesophageal reflux. The current standard of care for patients with BE includes serial performance of upper endoscopy with multiple biopsies, performed at designated time intervals. However, the emergence of new technologies for the management of this condition has made the care of these patients non-uniform, and subject to biases of individual treating physicians.
The protocol at The Valley Hospital and Blumenthal Cancer Center aims to standardize the management of patients with Barrett's esophagus, with and without dysplasia, using evidence-based, cutting edge diagnostic and therapeutic algorithms and techniques such as radiofrequency ablation, endoscopic mucosal resection, and surveillance endoscopy with biopsies. If biopsies suggest the development of carcinoma or high grade dysplasia surgical removal of the esophagus is recommended. This study aims to look at the long-term efficacy of these procedures. In addition, data regarding clinical outcomes will be collected as well as blood, tissue and surgical specimens for proteomic analysis in hopes of identifying biomarkers associated with the progression of dysplasia to adenocarcinoma. Although patients will ultimately make their own informed decisions regarding the management of their BE, this protocol serves to unify physician recommendations, and allows for the collection and interpretation of data.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New Jersey
-
Paramus, New Jersey, United States, 07652
- Valley Health System - The Valley Hospital - Luckow Pavilion
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female, age 18 to 85.
- Patient must have Barrett's Esophagus. Patients may be enrolled based on previous endoscopy reports and/or pathology reports. It is not necessary that each patient have endoscopy for the sole purpose of enrollment.
- Must agree to allow their clinical information to be collected, stored, analyzed and reported.
- Must allow portions of their biopsy/surgical specimens to be collected, stored, analyzed and reported.
- Must agree to fill out patient questionnaires in conjunction with the research study assistant assigned to this protocol (either in person or via telephone contact) at designated timepoints.
Exclusion Criteria:
- Intestinal metaplasia of the cardia, without an esophageal columnar lining.
- Unable to provide informed consent.
- Unable or unwilling to undergo endoscopic procedures.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Algorithm #1
Patients without visable lesions
|
Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports.
Repeat Endoscopic assessments are based on initial and follow-up assessments.
|
|
Algorithm #2
Patients with a visable lesion that is less than 1cm
|
Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports.
Repeat Endoscopic assessments are based on initial and follow-up assessments.
Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
Excision of lesion using DUETTE, marketed by Wilson-Cook
|
|
Algorithm #3
Patients with a visable lesion greater than 1cm
|
Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports.
Repeat Endoscopic assessments are based on initial and follow-up assessments.
Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
Excision of lesion using DUETTE, marketed by Wilson-Cook
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To standardize physician recommendations and provide cutting edge technology to patients with BE and GERD, and establish a Valley Hospital Center for Barrett's Esophagus and GERD
Time Frame: Until study complete
|
Until study complete
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To collect and store patient data regarding their Barrett's esophagus
Time Frame: Througout Study
|
Througout Study
|
|
To collect tissue specimens (biopsy and surgical specimens) for use in proteomic analysis to investigate the dysplasia/carcinoma sequence at the protein expression level.
Time Frame: throughout Study
|
throughout Study
|
|
To assess clinical outcomes of patients enrolled in The Valley Hospital Center for Barrett's Esophagus and GERD, and modify algorithms as appropriate.
Time Frame: Annually
|
Annually
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Robert J. Korst, MD, Valley Health Systems/ The Valley Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- VHS07.0017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GERD
-
NCT04901429Recruiting
-
NCT05089929Completed
-
NCT05108038Recruiting
-
NCT05282914Completed
-
NCT06141577Completed
-
NCT01230944Completed
Clinical Trials on Endoscopy
-
NCT01438385UnknownInterventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal DisordersColorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Cholangiocarcinoma | Bile Duct Cancer | Cholangitis | Barrett's Esophagus | Gallstones | Choledocholithiasis | Bile Leak
-
NCT06316882CompletedGastric Cancer | HELICOBACTER PYLORI INFECTIONS | Intestinal Metaplasia of Gastric Mucosa | Atrophic Gastritis | Gastric (Stomach) Cancer | High Grade Intraepithelial Neoplasia
-
NCT07481591Not yet recruitingGastrointestinal Bleeding
-
NCT05704010RecruitingLynch Syndrome | MLH1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | Lynch Syndrome II | Small Bowel Adenocarcinoma | Lynch Syndrome I
-
NCT02688114CompletedBarrett Esophagus
-
NCT01675856CompletedGastrointestinal Bleeding | Bleeding Peptic Ulcer | Active Bleeding
-
NCT02048033Terminatedthe Management of Weight Regain After Gastric Bypass by Endoscopic Suturing
-
NCT04605536Completed